Phase II study of neoadjuvant FLOT and chemoradiation for trimodality therapy of esophageal/GEJ adenocarcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium.
Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...
HOUSTON, TX, UNITED STATES, February 24, 2026 /EINPresswire.com/ — FamilyTreeDNA, the company that pioneered the genetic genealogy industry, today announced a ...
Myotonic dystrophy is thought to be caused by the binding of a protein called Mbnl1 to abnormal RNA repeats. In these two images of the same muscle precursor cell, the top image shows the location of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results